Latest & greatest articles for valsartan

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on valsartan or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on valsartan and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for valsartan

61. Valsartan for prevention of recurrent atrial fibrillation. (Abstract)

Valsartan for prevention of recurrent atrial fibrillation. Atrial fibrillation is the most common cardiac arrhythmia, and no current therapy is ideal for control of this condition. Experimental studies suggest that angiotensin II-receptor blockers (ARBs) can influence atrial remodeling, and some clinical studies suggest that they may prevent atrial fibrillation.We conducted a large, randomized, prospective, placebo-controlled, multicenter trial to test whether the ARB valsartan could reduce (...) the recurrence of atrial fibrillation. We enrolled patients who were in sinus rhythm but had had either two or more documented episodes of atrial fibrillation in the previous 6 months or successful cardioversion for atrial fibrillation in the previous 2 weeks. To be eligible, patients also had to have underlying cardiovascular disease, diabetes, or left atrial enlargement. Patients were randomly assigned to receive valsartan or placebo. The two primary end points were the time to a first recurrence of atrial

2009 NEJM Controlled trial quality: predicted high

62. An economic evaluation of valsartan for post-MI patients in the UK who are not suitable for treatment with ACE inhibitors Full Text available with Trip Pro

An economic evaluation of valsartan for post-MI patients in the UK who are not suitable for treatment with ACE inhibitors An economic evaluation of valsartan for post-MI patients in the UK who are not suitable for treatment with ACE inhibitors An economic evaluation of valsartan for post-MI patients in the UK who are not suitable for treatment with ACE inhibitors Taylor M, Scuffham P A, Chaplin S, Papo N L Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of valsartan for the treatment after myocardial infarction of patients with left ventricular systolic dysfunction, heart failure, or both, who were not suitable for treatment with angiotensin-converting enzyme inhibitors

2009 NHS Economic Evaluation Database.

63. Copalia - amlodipine / valsartan

Copalia - amlodipine / valsartan ©EMEA 2007 1/2929291 SCIENTIFIC DISCUSSION 1. Introduction The proper management and control of blood pressure in hypertension patients, and the impact it has on associated morbidity and mortality rates, has been the focus of many new hypertension observational studies and clinical trials. These trials have demonstrated that more aggressive blood pressure lowering will reduce the complications associated with hypertension. As a result of this data, international (...) . Therefore, the applicant was asked for a commitment to perform a separate study in elderly patients (see: follow-up measures). • Adverse events A literature search for the combination therapy did not provide any unknown AE or AES. Adverse events by primary system organ class generally show comparable incidences between the valsartan/amlodipine group, the monotherapy groups and the placebo groups. The most frequently occurring AE in the total valsartan/amlodipine group was peripheral edema. It occurred

2007 European Medicines Agency - EPARs

64. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. (Abstract)

Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. The aim of this study was to assess dual renin system intervention with the maximum recommended doses of aliskiren and valsartan, compared with each drug alone in patients with hypertension.In this double-blind study, 1797 patients with hypertension (mean sitting diastolic blood pressure 95-109 mm Hg and 8-h daytime ambulatory diastolic blood pressure > or =90 mm Hg (...) ) were randomly assigned to receive once-daily aliskiren 150 mg (n=437), valsartan 160 mg (455), a combination of aliskiren 150 mg and valsartan 160 mg (446), or placebo (459) for 4 weeks, followed by forced titration to double the dose to the maximum recommended dose for another 4 weeks. The primary endpoint was change in mean sitting diastolic blood pressure from baseline to week 8 endpoint. Analyses were done by intention to treat. This trial is registered at ClinicalTrials.gov with the number

2007 Lancet Controlled trial quality: predicted high

65. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. (Abstract)

Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Drugs that inhibit the renin-angiotensin-aldosterone system benefit patients at risk for or with existing cardiovascular disease. However, evidence for this effect in Asian populations is scarce. We aimed to investigate whether addition of an angiotensin receptor blocker, valsartan, to conventional cardiovascular (...) treatment was effective in Japanese patients with cardiovascular disease.We initiated a multicentre, prospective, randomised controlled trial of 3081 Japanese patients, aged 20-79 years, (mean 65 [SD 10] years) who were undergoing conventional treatment for hypertension, coronary heart disease, heart failure, or a combination of these disorders. In addition to conventional treatment, patients were assigned either to valsartan (40-160 mg per day) or to other treatment without angiotensin receptor

2007 Lancet Controlled trial quality: predicted high

66. Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: a budget impact analysis

Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: a budget impact analysis Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: a budget impact analysis Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: a budget impact analysis Smith D G, Cerulli A, Frech F H Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED (...) . Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined the addition of valsartan to usual care for the treatment of heart failure (HF) in patients not taking angiotensin-converting enzyme (ACE) inhibitors because of side effects or contraindications. Valsartan was given at a starting dose of 40 mg twice daily and titrated to a target

2005 NHS Economic Evaluation Database.

67. Markov modeling analysis of health and economic outcomes of therapy with valsartan versus amlodipine in patients with Type 2 diabetes and microalbuminuria

Markov modeling analysis of health and economic outcomes of therapy with valsartan versus amlodipine in patients with Type 2 diabetes and microalbuminuria Markov modeling analysis of health and economic outcomes of therapy with valsartan versus amlodipine in patients with Type 2 diabetes and microalbuminuria Markov modeling analysis of health and economic outcomes of therapy with valsartan versus amlodipine in patients with Type 2 diabetes and microalbuminuria Smith D G, Nguyen A B, Peak C N (...) , Frech F H Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared two treatment options for patients with Type 2 diabetes and microalbuminuria. The treatment options were the angiotensin II receptor blocker valsartan

2004 NHS Economic Evaluation Database.

68. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. (Abstract)

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial was designed to test the hypothesis that for the same blood-pressure control, valsartan would reduce cardiac morbidity and mortality more than amlodipine in hypertensive patients at high cardiovascular risk.15?245 patients, aged 50 years or older with treated or untreated (...) hypertension and high risk of cardiac events participated in a randomised, double-blind, parallel-group comparison of therapy based on valsartan or amlodipine. Duration of treatment was event-driven and the trial lasted until at least 1450 patients had reached a primary endpoint, defined as a composite of cardiac mortality and morbidity. Patients from 31 countries were followed up for a mean of 4.2 years.Blood pressure was reduced by both treatments, but the effects of the amlodipine-based regimen were

2004 Lancet Controlled trial quality: predicted high

69. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. Full Text available with Trip Pro

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. Angiotensin-converting-enzyme (ACE) inhibitors such as captopril reduce mortality and cardiovascular morbidity among patients with myocardial infarction complicated by left ventricular systolic dysfunction, heart failure, or both. In a double-blind trial, we compared the effect of the angiotensin-receptor blocker valsartan, the ACE inhibitor captopril, and the combination (...) of the two on mortality in this population of patients.Patients receiving conventional therapy were randomly assigned, 0.5 to 10 days after acute myocardial infarction, to additional therapy with valsartan (4909 patients), valsartan plus captopril (4885 patients), or captopril (4909 patients). The primary end point was death from any cause.During a median follow-up of 24.7 months, 979 patients in the valsartan group died, as did 941 patients in the valsartan-and-captopril group and 958 patients

2003 NEJM Controlled trial quality: predicted high

70. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. (Abstract)

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. Actions of angiotensin II may contribute to the progression of heart failure despite treatment with currently recommended drugs. We therefore evaluated the long-term effects of the addition of the angiotensin-receptor blocker valsartan to standard therapy for heart failure.A total of 5010 patients with heart failure of New York Heart Association (NYHA) class II, III, or IV were randomly assigned (...) to receive 160 mg of valsartan or placebo twice daily. The primary outcomes were mortality and the combined end point of mortality and morbidity, defined as the incidence of cardiac arrest with resuscitation, hospitalization for heart failure, or receipt of intravenous inotropic or vasodilator therapy for at least four hours.Overall mortality was similar in the two groups. The incidence of the combined end point, however, was 13.2 percent lower with valsartan than with placebo (relative risk, 0.87; 97.5

2001 NEJM Controlled trial quality: predicted high